Phathom Pharmaceuticals Inc expected to post a loss of $1.15 a share - Earnings Preview

Phathom Pharmaceuticals

29/04/2025 13:45

Phathom Pharmaceuticals Inc PHAT.OQ PHAT.O is expected to show a rise in quarterly revenue when it reports  results on May 1 for the period ending March 31 2025

The Florham Park New Jersey-based  company is expected to report a 1,417.6% increase in revenue to $29.016 million from $1.91 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Phathom Pharmaceuticals Inc is for a loss of $1.15 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 0.3% in the last three months. ​

Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $21.00​, above​ its last closing price of $4.15. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.31
-1.27
-1.05
Beat
17.4
Sep. 30 2024
-1.59
-1.49
-1.32
Beat
11.7
Jun. 30 2024
-1.40
-1.38
-1.56
Missed
-13​
Mar. 31 2024
-1.28
-1.31
-1.42
Missed
-8.5
​​Dec. 31 2023
-1.10
-1.08
-1.39
Missed
-29.1
Sep. 30 2023
-0.87
-0.89
-0.76
Beat
14.7​
Jun. 30 2023
-0.94
-0.98
-0.84
Beat
14.2
Mar. 31 2023
-1.23
-1.26
-0.89
Beat
29.4

This summary was machine generated April 29 at 12:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)